Gilead

Possibility of positive developments on the product pipeline front and restructuring initiatives can accelerate earnings growth for Lupin. We continue to believe this opportunity is more suitable for investors with high risk appetite and those who are ready to hold it long enough for the product pipeline to unfold

Lupin: Focus on inhalation and bio-similars to aid margins in medium term

In the medium term, the focus is likely to be on the inhalation and biosimilar categories for Lupin, with scale-up in both US and European markets

COVID-19 update: Gilead announces steps to boost remdesivir production in India, donates 4.5 lakh vials

Remdesivir is approved in India for restricted emergency use for the treatment of COVID-19 in adults and children hospitalised with severe disease.

European Union executive signs remdesivir deal with Gilead

Spinant said the contract was worth 63 million euros ($73.99 million) and would provide treatment to 30,000 patients with severe COVID-19 symptoms.

Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations

The price tag is slightly below the range of $2,520 to $2,800 suggested last week by U.S. drug pricing research group the Institute for Clinical and Economic Review (ICER) after British researchers said they found that the cheap, widely available steroid dexamethasone significantly reduced mortality among severely ill COVID-19 patients.

US group raises pricing recommendation for Gilead's remdesivir in COVID-19

The Institute for Clinical and Economic Review (ICER) said its recommendation change stemmed from recent clinical data, updated cost estimates, public comments and interactions with Gilead.

COVID-19 treatment | Gilead to begin clinical trials of inhaled version of remdesivir

Gilead Sciences says it also expects to supply remdesivir to treat more than two million COVID-19 patients by year-end.

Gilead targets remdesivir supply for two million COVID-19 patients by year-end

Gilead Sciences has said it hopes to start trials in August of an easier-to-use inhaled version of remdesivir, currently administered only intravenously.

GSK is world's largest vaccine maker. Yet it has been tame with its COVID-19 strategy

GSK is betting on its adjuvant technology to support companies developing COVID-19 vaccines.

BDR Pharmaceuticals seeks drug controller’s nod to manufacture generic version of Remdesivir, irks Gilead: Report

Raising concerns, Gilead has reportedly written to the Prime Minister’s Office, the Union Health Ministry and NITI Aayog, among others.

Explained | COVID-19: Gilead licensing agreement of Remdesivir

In this episode of the Explained series, understand what does the licensing agreements mean for the fight against COVID-19.

U.S. to allow states to distribute Gilead's remdesivir to fight COVID-19

Gilead has committed to supply approximately 607,000 vials of remdesivir over the next six weeks in the United States, and the U.S. state health department will distribute the doses to appropriate hospitals in their states, HHS said.

Coronavirus pandemic | Gilead could face compulsory licensing despite patents if supply fails demand: Report

There is a chance Gilead may work out its own licensing deals before being forced into CL by the government.

Gilead in talks to expand global supply of COVID-19 drug remdesivir

Gilead Sciences Inc said on Tuesday it was in discussions with chemical and drug manufacturers to produce its experimental COVID-19 drug remdesivir for Europe, Asia and the developing world through at least 2022.

Gilead's Remdesivir meets main goal of trial in COVID-19 patients

The closely-watched drug has moved markets in the past few weeks and on Wednesday broader markets once again rose on the data and Gilead shares also jumped 9%.

COVID-19 drug | India not keen to ask Gilead to issue compulsory licence: Report

Remdesivir, originally developed to treat Ebola more than a decade ago, is said to be one of the more promising drugs being tested to treat COVID-19.

Gilead disputes report that its drug flopped in leaked coronavirus trial

Interest in Gilead's remdesivir has been high as there are currently no approved treatments or preventive vaccines for COVID-19, and doctors are desperate for anything that might alter the course of the disease that attacks the lungs and can shut down other organs in extremely severe cases.

Institutional investors tell Big Pharma to cooperate on coronavirus

While drugmakers have sprung into action to try and come up with vaccines to treat the coronavirus and test for the presence of COVID-19 and other measures, investors say they need to do more.

Gilead shares surge after report says COVID-19 patients respond to remdesivir

A University of Chicago hospital participating in a study of the antiviral medication said it is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, according to medical news website STAT.

Coronavirus pandemic| Under pressure, Gilead says will try to make remdesivir affordable

The American firm is conducting Phase III clinical trials for remdesivir, a potential drug for COVID-19

Natco net profit surges five-fold to Rs 195 crore in Q3

The revenue and profit growth for the company during the quarter was driven predominantly by the sales of Oseltamivir product or generic Tamiflu in the US market and includes profit sharing from our marketing partner, Natco said in a statement.

Mylan launches generic hepatitis C drug MyHep in India

Mylan launches generic hepatitis C drug MCompany's Indian arm Mylan Pharmaceuticals has launched generic Sofosbuvir tablets in strength of 400 mg under the name MyHep in the countryyHep in India

Hope for Hepatitis C-affected Indians

US-based Gilead's revoluntionary drug Sofosbuvir will finally be available in India at a fraction of its original cost, thanks to licensing agreements with seven generic companies.

Cadila Health up 3%, diabetic drug gets tentative USFDA nod

"Zydus Cadila has received tentative approval from the US Food and Drug Administration (US FDA) to market (anti-diabetic drug) Glipizide extended release tablets in the strength of 2.5 mg, 5 mg and 10 mg," said the company in its filing.